Vikas Prasad

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8143610/publications.pdf

Version: 2024-02-01

130	3,886	159585	133252
papers	citations	30 h-index	59 g-index

143	143	143	4266
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	German Multicenter Study Investigating¹⁷⁷Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients. Journal of Nuclear Medicine, 2017, 58, 85-90.	5.0	646
2	Molecular Imaging of HER2-Expressing Malignant Tumors in Breast Cancer Patients Using Synthetic ¹¹¹In- or ⁶⁸Ga-Labeled Affibody Molecules. Journal of Nuclear Medicine, 2010, 51, 892-897.	5.0	271
3	Detection of unknown primary neuroendocrine tumours (CUP-NET) using 68Ga-DOTA-NOC receptor PET/CT. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 67-77.	6.4	229
4	Molecular imaging with 68Ga-SSTR PET/CT and correlation to immunohistochemistry of somatostatin receptors in neuroendocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 1659-1668.	6.4	130
5	Immunohistochemical Validation of PSMA Expression Measured by ⁶⁸Ga-PSMA PET/CT in Primary Prostate Cancer. Journal of Nuclear Medicine, 2018, 59, 238-243.	5.0	120
6	Results and adverse events of personalized peptide receptor radionuclide therapy with 90Yttrium and 177Lutetium in 1048 patients with neuroendocrine neoplasms. Oncotarget, 2018, 9, 16932-16950.	1.8	109
7	Streptozocin/5-fluorouracil chemotherapy is associated with durable response in patients with advanced pancreatic neuroendocrine tumours. European Journal of Cancer, 2015, 51, 1253-1262.	2.8	95
8	The Status of Neuroendocrine Tumor Imaging: From Darkness to Light?. Neuroendocrinology, 2015, 101, 1-17.	2.5	92
9	NET Blood Transcript Analysis Defines the Crossing of the Clinical Rubicon: When Stable Disease Becomes Progressive. Neuroendocrinology, 2017, 104, 170-182.	2.5	87
10	Biodistribution of [68Ga]PSMA-HBED-CC in Patients with Prostate Cancer: Characterization of Uptake in Normal Organs and Tumour Lesions. Molecular Imaging and Biology, 2016, 18, 428-436.	2.6	84
11	Biodistribution of the Ga-68 labeled somatostatin analogue DOTA-NOC in patients with neuroendocrine tumors: characterization of uptake in normal organs and tumor lesions. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2010, 54, 61-7.	0.7	84
12	A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management. Endocrine Connections, 2016, 5, 174-187.	1.9	83
13	PET/CT imaging of osteoblastic bone metastases with 68Ga-bisphosphonates: first human study. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 834-834.	6.4	80
14	Neoadjuvant peptide receptor radionuclide therapy for aninoperable neuroendocrine pancreatic tumor. World Journal of Gastroenterology, 2009, 15, 5867.	3.3	80
15	Cost comparison of 111In-DTPA-octreotide scintigraphy and 68Ga-DOTATOC PET/CT for staging enteropancreatic neuroendocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 72-82.	6.4	76
16	2017 GPOH Guidelines for Diagnosis and Treatment of Patients with Neuroblastic Tumors. Klinische Padiatrie, 2017, 229, 147-167.	0.6	76
17	Comparison of hybrid 68Ga-PSMA-PET/CT and 99mTc-DPD-SPECT/CT for the detection of bone metastases in prostate cancer patients: Additional value of morphologic information from low dose CT. European Radiology, 2018, 28, 610-619.	4.5	59
18	Receptor PET/CT Imaging of Neuroendocrine Tumors. Recent Results in Cancer Research, 2008, 170, 225-242.	1.8	54

#	Article	IF	Citations
19	The Bad Berka Dose Protocol: Comparative Results of Dosimetry in Peptide Receptor Radionuclide Therapy Using 177Lu-DOTATATE, 177Lu-DOTANOC, and 177Lu-DOTATOC. Recent Results in Cancer Research, 2013, 194, 519-536.	1.8	51
20	Comparison of sequential planar 177Lu-DOTA-TATE dosimetry scans with 68Ga-DOTA-TATE PET/CT images in patients with metastasized neuroendocrine tumours undergoing peptide receptor radionuclide therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 501-511.	6.4	48
21	Role of 68Ga somatostatin receptor PET/CT in the detection of endogenous hyperinsulinaemic focus: an explorative study. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1593-1600.	6.4	48
22	Prognostic Significance of Somatostatin Receptor Heterogeneity in Progressive Neuroendocrine Tumor Treated with Lu-177 DOTATOC or Lu-177 DOTATATE. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 881-894.	6.4	47
23	Effect of Peptide Receptor Radionuclide Therapy on Somatostatin Receptor Status and Glucose Metabolism in Neuroendocrine Tumors: Intraindividual Comparison of Ga-68 DOTANOC PET/CT and F-18 FDG PET/CT. International Journal of Molecular Imaging, 2011, 2011, 1-7.	1.3	46
24	Gene transcript analysis blood values correlate with 68Ga-DOTA-somatostatin analog (SSA) PET/CT imaging in neuroendocrine tumors and can define disease status. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1341-1352.	6.4	43
25	Peptide receptor radionuclide therapy of Merkel cell carcinoma using 177lutetium-labeled somatostatin analogs in combination with radiosensitizing chemotherapy: a potential novel treatment based on molecular pathology. Annals of Nuclear Medicine, 2012, 26, 365-369.	2.2	42
26	European Neuroendocrine Tumor Society (<scp>ENETS</scp>) 2022 Guidance Paper for Carcinoid Syndrome and Carcinoid Heart Disease. Journal of Neuroendocrinology, 2022, 34, .	2.6	39
27	Imaging-based evaluation of liver function: comparison of 99mTc-mebrofenin hepatobiliary scintigraphy and Gd-EOB-DTPA-enhanced MRI. European Radiology, 2015, 25, 1384-1391.	4.5	34
28	Mesenteric Fibrosis in Midgut Neuroendocrine Tumors: Functionality and Radiological Features. Neuroendocrinology, 2018, 106, 139-147.	2.5	33
29	Dosimetric comparison of different treatment modalities for stereotactic radiosurgery of meningioma. Acta Neurochirurgica, 2015, 157, 559-564.	1.7	32
30	Potential role of 68Ga-DOTATOC PET/CT in screening for pancreatic neuroendocrine tumour in patients with von Hippel-Lindau disease. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 2014-2020.	6.4	31
31	Radioguided Surgery in Neuroendocrine Tumors Using Ga-68-Labeled Somatostatin Analogs. Clinical Nuclear Medicine, 2012, 37, 142-147.	1.3	30
32	The search for the primary tumor in metastasized gastroenteropancreatic neuroendocrine neoplasm. Clinical and Experimental Metastasis, 2014, 31, 817-827.	3.3	30
33	Diagnostic imaging of pancreatic neuroendocrine neoplasms (pNEN): tumor detection, staging, prognosis, and response to treatment. Acta Radiologica, 2016, 57, 260-270.	1.1	29
34	68Ga-PSMA-PET/CT for the evaluation of liver metastases in patients with prostate cancer. Cancer Imaging, 2019, 19, 37.	2.8	28
35	Functional Imaging in the Follow-Up of Enteropancreatic Neuroendocrine Tumors: Clinical Usefulness and Indications. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 1486-1494.	3.6	27
36	Octreotide Does Not Inhibit Proliferation in Five Neuroendocrine Tumor Cell Lines. Frontiers in Endocrinology, 2018, 9, 146.	3.5	26

#	Article	IF	Citations
37	Interobserver variability, detection rate, and lesion patterns of 68Ga-PSMA-11-PET/CT in early-stage biochemical recurrence of prostate cancer after radical prostatectomy. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2339-2347.	6.4	26
38	EDIM-TKTL1 blood test: a noninvasive method to detect upregulated glucose metabolism in patients with malignancies. Future Oncology, 2012, 8, 1349-1359.	2.4	25
39	[68Ga]PSMA-HBED-CC Uptake in Osteolytic, Osteoblastic, and Bone Marrow Metastases of Prostate Cancer Patients. Molecular Imaging and Biology, 2017, 19, 933-943.	2.6	23
40	Peritoneal Carcinomatosis in Gastro-Entero-Pancreatic Neuroendocrine Neoplasms: Clinical Impact and Effectiveness of the Available Therapeutic Options. Neuroendocrinology, 2020, 110, 517-524.	2.5	22
41	FDG-PET/CT in Lung Cancer: An Update. Frontiers of Radiation Therapy and Oncology, 2009, 42, 15-45.	1.4	18
42	In Comparison to PSA, Interim Ga-68-PSMA PET/CT Response Evaluation Based on Modified RECIST 1.1 After 2nd Cycle Is Better Predictor of Overall Survival of Prostate Cancer Patients Treated With 177Lu-PSMA. Frontiers in Oncology, 2021, 11, 578093.	2.8	18
43	Pancreatic Neuroendocrine Tumor With Involvement of the Inferior Mesenteric Vein Diagnosed by Ga-68 DOTA-TATE PET/CT. Clinical Nuclear Medicine, 2010, 35, 40-41.	1.3	17
44	Somatostatin receptor PET/CT in restaging of typical and atypical lung carcinoids. EJNMMI Research, 2015, 5, 53.	2.5	17
45	Tumor Lysis Syndrome: A Rare but Serious Complication of Radioligand Therapies. Journal of Nuclear Medicine, 2019, 60, 752-755.	5.0	17
46	Synoptic reporting of echocardiography in carcinoid heart disease (ENETS Carcinoid Heart Disease) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	2.6	16
47	First experiences with Lu-177 PSMA therapy in combination with Pembrolizumab or after pretreatment with Olaparib in single patients. Journal of Nuclear Medicine, 2021, 62, jnumed.120.249029.	5.0	15
48	Multimodal Imaging of 2-Cycle PRRT with ¹⁷⁷Lu-DOTA-JR11 and ¹⁷⁷Lu-DOTATOC in an Orthotopic Neuroendocrine Xenograft Tumor Mouse Model. Journal of Nuclear Medicine, 2021, 62, 393-398.	5.0	14
49	ENETS standardized (synoptic) reporting for radiological imaging in neuroendocrine tumours. Journal of Neuroendocrinology, 2022, 34, e13044.	2.6	14
50	T Cell PTLD Successfully Treated With Single-Agent Brentuximab Vedotin First-Line Therapy. Transplantation, 2016, 100, e8-e10.	1.0	13
51	Effect of Tumor Perfusion and Receptor Density on Tumor Control Probability in ¹⁷⁷Lu-DOTATATE Therapy: An In Silico Analysis for Standard and Optimized Treatment. Journal of Nuclear Medicine, 2021, 62, 92-98.	5.0	13
52	Gastric neuroendocrine neoplasias: manifestations and comparative outcomes. Endocrine-Related Cancer, 2019, 26, 751-763.	3.1	13
53	Analysis of Somatostatin Receptor 2A Immunohistochemistry, RT-qPCR, and In Vivo PET/CT Data in Patients With Pancreatic Neuroendocrine Neoplasm. Pancreas, 2015, 44, 648-654.	1.1	12
54	Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors. Frontiers of Hormone Research, 2015, 44, 198-215.	1.0	12

#	Article	IF	Citations
55	Identification of Speed-Dependent Active Magnetic Bearing Parameters and Rotor Balancing in High-Speed Rotor Systems. Journal of Dynamic Systems, Measurement and Control, Transactions of the ASME, 2019, 141, .	1.6	12
56	ENETS standardized (synoptic) reporting for molecular imaging studies in neuroendocrine tumours. Journal of Neuroendocrinology, 2022, 34, e13040.	2.6	12
57	ENETS standardized (synoptic) reporting for endoscopy in neuroendocrine tumors. Journal of Neuroendocrinology, 2022, 34, e13105.	2.6	12
58	Combined measurement of tumor perfusion and glucose metabolism for improved tumor characterization in advanced cervical carcinoma. Strahlentherapie Und Onkologie, 2014, 190, 575-581.	2.0	11
59	PET/CT in Neuroendocrine Tumors: Evaluation of Receptor Status and Metabolism. PET Clinics, 2007, 2, 351-375.	3.0	10
60	Intense 18F-Fluoride Accumulation in Liver Metastases From a Neuroendocrine Tumor After Peptide Receptor Radionuclide Therapy. Clinical Nuclear Medicine, 2012, 37, e82-e83.	1.3	10
61	Efficacy of indigenously developed single vial kit preparation of 99mTc-ciprofloxacin in the detection of bacterial infection: an Indian experience. Nuclear Medicine Communications, 2008, 29, 1123-1129.	1.1	9
62	Combination of Structural MRI andÂFDG-PET of the Brain Improves Diagnostic Accuracy in Newly Manifested Cognitive Impairment in Geriatric Inpatients. Journal of Alzheimer's Disease, 2016, 54, 1319-1331.	2.6	9
63	Quantitative in vivo fusion assessment by 18F-fluoride PET/CT following en bloc spondylectomy. European Spine Journal, 2016, 25, 836-842.	2.2	9
64	Management of follow-up of neuroendocrine neoplasias. Best Practice and Research in Clinical Endocrinology and Metabolism, 2016, 30, 129-140.	4.7	9
65	Lessons from a multicentre retrospective study of peptide receptor radionuclide therapy combined with lanreotide for neuroendocrine tumours: a need for standardised practice. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2358-2371.	6.4	9
66	Target Heterogeneity in Oncology: The Best Predictor for Differential Response to Radioligand Therapy in Neuroendocrine Tumors and Prostate Cancer. Cancers, 2021, 13, 3607.	3.7	9
67	A Physiologically Based Pharmacokinetic Model for In Vivo Alpha Particle Generators Targeting Neuroendocrine Tumors in Mice. Pharmaceutics, 2021, 13, 2132.	4.5	9
68	Intraoperative Somatostatin Receptor Detection After Peptide Receptor Radionuclide Therapy with 177Lu- and 90Y-DOTATOC (Tandem PRRNT) in a Patient with a Metastatic Neuroendocrine Tumor. Recent Results in Cancer Research, 2013, 194, 487-496.	1.8	8
69	The future of nuclear medicine imaging of neuroendocrine tumors: on a clear day one might see foreverâ€¦. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 2189-2193.	6.4	8
70	How smart is peptide receptor radionuclide therapy of neuroendocrine tumors especially in the salvage setting? The clinicianâ€™s perspective. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 202-204.	6.4	8
71	Nephrotoxicity after radionuclide therapies. Translational Oncology, 2022, 15, 101295.	3.7	8
72	Short-Interval, Low-Dose Peptide Receptor Radionuclide Therapy in Combination with PD-1 Checkpoint Immunotherapy Induces Remission in Immunocompromised Patients with Metastatic Merkel Cell Carcinoma. Pharmaceutics, 2022, 14, 1466.	4.5	8

#	Article	IF	Citations
73	Whither peptide receptor radionuclide therapy for neuroendocrine tumors: an Einsteinian view of the facts and myths. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1825-1830.	6.4	7
74	Challenges in Screening and Recruitment for a Neuroimaging Study in Cognitively Impaired Geriatric Inpatients. Journal of Alzheimer's Disease, 2017, 56, 197-204.	2.6	7
75	Pattern recognition in thought form images using chromaticity parameters. , 2017, , .		7
76	Changes of Radiation Treatment Concept Based on 68Ga-PSMA-11-PET/CT in Early PSA-Recurrences After Radical Prostatectomy. Frontiers in Oncology, 2021, 11, 665304.	2.8	7
77	Somatostatin receptor immunohistochemistry in neuroendocrine tumors: comparison between manual and automated evaluation. International Journal of Clinical and Experimental Pathology, 2014, 7, 4971-80.	0.5	7
78	Contemporary options and future perspectives: three examples highlighting the challenges in testicular cancer imaging. World Journal of Urology, 2021, , 1.	2.2	7
79	Comparison of Choi, RECIST and Somatostatin Receptor PET/CT Based Criteria for the Evaluation of Response and Response Prediction to PRRT. Pharmaceutics, 2022, 14, 1278.	4.5	7
80	The impact of 18â€‰F-FET PET-CT on target definition in image-guided stereotactic radiotherapy in patients with skull base lesions. Cancer Imaging, 2014, 14, 25.	2.8	6
81	Clinical trials involving positron emission tomography and prostate cancer: an analysis of the ClinicalTrials.gov database. Radiation Oncology, 2018, 13, 113.	2.7	6
82	Accuracy of standard clinical 3T prostate MRI for pelvic lymph node staging: Comparison to 68Ga-PSMA PET-CT. Scientific Reports, 2019, 9, 10727.	3.3	6
83	Longterm outcome of peptide receptor radionuclide therapy (PRRT) in 454 patients with progressive neuroendocrine tumors using yttrium-90 and lutetium-177 labelled somatostatin receptor targeting peptides. Journal of Clinical Oncology, 2008, 26, 4517-4517.	1.6	6
84	PET/CT in Neuroendocrine Tumors: Evaluation of Receptor Status and Metabolism. PET Clinics, 2008, 3, 355-379.	3.0	5
85	Potential of asphericity as a novel diagnostic parameter in the evaluation of patients with 68Ga-PSMA-HBED-CC PET-positive prostate cancer lesions. EJNMMI Research, 2017, 7, 85.	2.5	5
86	Pattern Recognition in Thought-Form Images Using Radon Transform and Histograms. , 2017, , .		5
87	Study evaluating metastatic castrate resistant prostate cancer (mCRPC) treatment using ¹⁷⁷Lu-PNT2002 PSMA therapy after second-line hormonal treatment (SPLASH).. Journal of Clinical Oncology, 2021, 39, TPS5087-TPS5087.	1.6	5
88	A Multi-Institutional Analysis of Prostate Cancer Patients With or Without 68Ga-PSMA PET/CT Prior to Salvage Radiotherapy of the Prostatic Fossa. Frontiers in Oncology, 2021, 11, 723536.	2.8	5
89	A family with pheochromocytoma-paraganglioma inherited tumour syndrome. Nuklearmedizin - NuclearMedicine, 2016, 55, 34-40.	0.7	5
90	Diagnosis of Mandibular Osteomyelitis in Probable Coexisting Tumor Recurrence: Role of Tc-99m Ciprofloxacin Imaging. Clinical Nuclear Medicine, 2008, 33, 525-527.	1.3	4

#	Article	IF	Citations
91	Diagnostic accuracy of 99mTc-MIBI-SPECT in the detection of lymph node metastases in patients with carcinoma of the tongue: comparison with computed tomography and MRI. Nuclear Medicine Communications, 2008, 29, 803-808.	1.1	4
92	FDG PET correlates weakly with HIF-1Î± expression in solid tumors: a meta-analysis. Acta Radiologica, 2021, 62, 557-564.	1.1	4
93	mTOR Inhibitors as Radiosensitizers in Neuroendocrine Neoplasms. Frontiers in Oncology, 2020, 10, 578380.	2.8	3
94	Abstract PO-077: Study evaluating metastatic castrate resistant prostate cancer (mCRPC) treatment using 177Lu-PNT2002 PSMA therapy after second-line hormonal treatment (SPLASH) - Trial in progress. Clinical Cancer Research, 2021, 27, PO-077-PO-077.	7.0	3
95	68Ga-NODAGA-exendin-4 PET/CT for the localization of insulinomas. Nuklearmedizin - NuclearMedicine, 2019, 58, .	0.7	3
96	Optimized separation of left and right liver lobe in dynamic 99mTc-mebrofenin hepatobiliary scintigraphy using a hybrid SPECT-CT scanner. Annals of Nuclear Medicine, 2014, 28, 897-902.	2.2	2
97	Unique Color Circle Design For A Novel Screening Tool to Identify Cancerous Skin Lesions. , 2020, , .		2
98	PSMA Theranostics: Is the Time Ripe to Pave the Way to Further Tumor Entities?. Journal of Nuclear Medicine, 2021, 62, 1242-1243.	5.0	2
99	Safety and efficacy of 177lu-PSMA-617 radioligand therapy in patients with mCRPC: A multicenter study.. Journal of Clinical Oncology, 2017, 35, 155-155.	1.6	2
100	Safety and survival outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with lutetium-177â€“prostate-specific membrane antigen (¹⁷⁷Lu-PSMA) after radium-223 (²²³Ra): Interim analysis of the RALU study.. Journal of Clinical Oncology, 2022, 40, 5040-5040.	1.6	2
101	2-deoxy-2-[18]fluoro-D-glucose PET/CT (18FDG PET/CT) may not be a viable biomarker in Pompe disease. Human Genomics, 2018, 12, 14.	2.9	1
102	Can Met-PET/CT Predict Sporadic Multiglandular Hyperparathyroidism? Report of a Case and Review of the Literature. Case Reports in Endocrinology, 2019, 2019, 1-4.	0.4	1
103	Identification of â€˜Manasâ€™ (States of Mind): Simulation Studies in Biophotonics. , 2020, , .		1
104	Comparison of MRI-based and PET-based image pre-processing for quantification of 11C-PBB3 uptake in human brain. Zeitschrift Fur Medizinische Physik, 2021, 31, 37-47.	1.5	1
105	Non-invasive Imaging in Patients With Chronic Total Occlusions of the Coronary Arteriesâ€”What Does the Interventionalist Need for Success?. Frontiers in Cardiovascular Medicine, 2021, 8, 713625.	2.4	1
106	Effect of peptide dose on radiation dosimetry for peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATOC: A pilot study. Indian Journal of Nuclear Medicine, 2021, 36, 412.	0.3	1
107	Dynamic 18F-FET PET/CT to differentiate recurrent primary brain tumor and brain metastases from radiation necrosis after single-session robotic radiosurgery. Cancer Treatment and Research Communications, 2022, 32, 100583.	1.7	1
108	73 poster: Molecular Remission after Neoadjuvant Chemoradiation in Mediastinal Lymph Node Metastases as Detected by F-18 FDG PET in Patients with NSCLC. Radiotherapy and Oncology, 2010, 94, S29.	0.6	0

#	Article	IF	Citations
109	79 poster: Are Timing of Chemoradiation and Early Therapy Response as Detected by F-18 FDG PET Prognostic Factors of a Multimodality Treatment Approach for NSCLC Stage III?. Radiotherapy and Oncology, 2010, 94, S31.	0.6	0
110	Reply: Diagnosis of neuroendocrine tumours and the costs for different tracers â€“ the real problem behind the scenes!. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 725-726.	6.4	0
111	P2-230: Sixty-Six Percent Screen Failures in a Prospective Multicenter Neuroimaging Trial on the Diagnosis of Clinically Uncertain Cognitive Impairment in Geriatric Inpatients. , 2016, 12, P710-P711.		0
112	ICâ€Pâ€119: Improved Diagnostic Accuracy in Newly Manifested Cognitive Impairment in Geriatric Inpatients: A Multicenter MRI and Pet Study. Alzheimer's and Dementia, 2016, 12, P89.	0.8	0
113	341 Neuroendocrine Tumor Blood Transcript Analysis, the NETest, Predicts Gastroenteropancreatic Neuroendocrine Tumor Disease Status and Is Prognostic for Progressive Disease. Gastroenterology, 2016, 150, S80-S81.	1.3	0
114	761 Circulating Neuroendocrine Gene Transcripts Accurately Identify GEP-NETs, Are Decreased by Surgery and Predict Tumor Progression and Recurrence. Gastroenterology, 2016, 150, S154.	1.3	0
115	Orthotopic versus subcutaneous NET: tumor tissue characteristics result in different answers when ADC is used to validate early therapy response following Peptide Receptor Radionuclide Therapy (PRRT). Annals of Oncology, 2017, 28, v598.	1.2	0
116	Why wait for posterity (or the future) to provide proof to savor the elixir of precision oncology? Read interviews with intellects and dine with the doyens of discovery. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2418-2420.	6.4	0
117	Evaluating Biofield Therapy Effects Using Unique Color Circle Design Implementable in Biophotonics Lab. , 2020, , .		0
118	A Novel Screening Tool to Identify Cancerous Skin Lesions in Biophotonics. , 2020, , .		0
119	Streptozocin-based chemotherapy in patients with advanced pancreatic neuroendocrine tumors.. Journal of Clinical Oncology, 2014, 32, 295-295.	1.6	0
120	Outcome predictors of gastrinomas: The role of ENETS staging, grading and interdisciplinary treatment. Experimental and Clinical Endocrinology and Diabetes, 2014, 122, .	1.2	0
121	Gastric neuroendocrine neoplasias â€“ Outcome predictors â€“ ENETS staging and grading system and treatment. Experimental and Clinical Endocrinology and Diabetes, 2015, 122, .	1.2	0
122	Lanreotide depot/autogel before, during, and after peptide receptor radionuclide therapy (PRRT) in advanced neuroendocrine tumors (NETs): Data from the PRELUDE study.. Journal of Clinical Oncology, 2018, 36, e16167-e16167.	1.6	0
123	Lanreotide depot/autogel before, during, and after peptide receptor radionuclide therapy (PRRT) in advanced neuroendocrine tumors (NETs): Data from the PRELUDE study. Endocrine Abstracts, 0, , .	0.0	0
124	Evaluation des prognostischen Wertes der Texturanalyse der F-18-FDG-PET/CT bei Knochensarkomen. , 2019, 58, .		0
125	Evaluation des prognostischen und prÃdiktiven Wertes der Iod-123-MIBG-SPECT/CT bei Neuroblastomen. , 2019, 58, .		0
126	Tau PET/CT Bildgebung mit C-11-PBB3 in Patienten mit Verdacht auf neurodegenerative Erkrankungen des AD- und FTLD-Spektrums. , 2019, 58, .		0

#	Article	IF	Citations
127	Prognostischer Wert der F-18-FDG-PET/CT inklusive Texturanalyse bei NSCLC: AbhÃngigkeit von Grading und Histologie. Nuklearmedizin - NuclearMedicine, 2019, 58, .	0.7	0
128	Prognostischer Wert der Texturanalyse und bildbasierter Biomarker der MRT und Iod-123-MIBG-Szintigrafie bei Neuroblastom-Patienten. , 2019, 58, .		0
129	Regional tau deposition in probable Alzheimerâ€™s disease using C-11-PBB3-PET: a voxel-wise statistical analysis. Nuklearmedizin - NuclearMedicine, 2020, 59, .	0.7	0
130	Nuclear medicine therapy of lung cancer, breast cancer and colorectal cancer. , 2022, , .		0